The Jeonnam Hwasun Microbial Validation Support Center (hereinafter referred to as the Center) announced on the 12th that it signed a business agreement (MOU) with bio company Alpexbio Co., Ltd. for the development of mRNA-based pharmaceuticals. This agreement was established to establish a cooperative system between the two organizations with the goal of developing and commercializing a pipeline using mRNA source technology.
The two organizations plan to pursue comprehensive cooperation for the development of vaccines and treatments based on mRNA technology, including planning and conducting joint research and development projects. AlpexBio is setting its main tasks as process establishment, new platform development, and expansion of cooperation with domestic companies based on mRNA and self-replicating RNA source technologies.
The center plans to provide CDMO (contract development and manufacturing organization) services, including technical consulting and product production, based on mRNA process development and manufacturing infrastructure based on GMP (Good Manufacturing Practice). In particular, it is building a full-cycle production system that can support everything from non-clinical samples to national emergency response vaccine production, and plans to complete mRNA-dedicated manufacturing facilities and prefilled syringe lines by next year.
AlpexBio is a bio company focusing on the development of RNA vaccines and therapeutics, and has a diverse pipeline of infectious disease response drugs based on its experience in developing COVID-19 mRNA vaccines. Based on its own mRNA platform technology and RNA virus-based vaccine technology, it is focusing on improving safety and efficacy through the use of unmodified nucleic acids.
A center official said, “This agreement is a representative example of mRNA technology cooperation between public institutions and private companies, and is expected to contribute to strengthening the competitiveness of the domestic bio industry and domestic production of vaccines and treatments.” The two organizations plan to continue their cooperation in the future to build a bio ecosystem based on technological independence.
- See more related articles
You must be logged in to post a comment.